GLP Watchdog

Hims vs MEDVi

Hims has an open FDA warning letter dated September 9, 2025. MEDVi has an open FDA warning letter dated February 20, 2026. No price lines up like for like: Hims and MEDVi publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hims / MEDVi

Hims logo

Hims

6.7/10

MEDVi logo

MEDVi

7.7/10

FDA warning letters
Pharmacy
Lowest standing price
$149/moBrand-name semaglutide pill, medication only, membership extra
$199/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit Hims
Visit MEDVi

Neither Hims nor MEDVi pays us. Links to them earn nothing. Scores: Hims 6.7, MEDVi 7.7. How we are paid

What the record shows

  1. 01

    Hims has an open FDA warning letter dated September 9, 2025. MEDVi has an open FDA warning letter dated February 20, 2026.

  2. 02

    MEDVi names three pharmacies, all 503A. Hims sells brand-name medication only.

  3. 03

    No price lines up like for like: Hims and MEDVi publish prices for different products.

  4. 04

    Only Hims lists a price for brand-name semaglutide pen, brand-name tirzepatide pen and brand-name semaglutide pill. Only MEDVi lists a price for compounded semaglutide injection.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hims

MEDVi

Compounded semaglutide injection
Not sold or not priced

$199/mo

$2,388 a year

Brand-name semaglutide pen

$199/mo

medication only, membership extra; not compared

Not sold or not priced
Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Brand-name semaglutide pill

$149/mo

medication only, membership extra; not compared

Not sold or not priced
Foundayo (orforglipron) pill

$149/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Medication, clinician visits, shipping, coaching
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
Monthly membership, auto-renews
None; billed monthly
Refunds
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
Full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed
Early-exit fee
None stated
None stated

Read off each seller’s own pages. Hims: October 17, 2026. MEDVi: October 25, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hims

6.7/10
  • Sells brand-name semaglutide pen and brand-name tirzepatide pen, which MEDVi does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

The case for MEDVi

7.7/10
  • Sells compounded semaglutide injection, which Hims does not price
  • Price includes clinician visits and coaching
  • Open FDA warning letter, February 20, 2026
Visit MEDVi

Scores

Hims 6.7 · MEDVi 7.7 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
5.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
6.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

3.0A
vs
B
8.5

The score is the same formula for every seller. Payment does not enter it. Method

Hims vs MEDVi: questions

Hims has an open FDA warning letter dated September 9, 2025. MEDVi has an open FDA warning letter dated February 20, 2026. Letters are matched to a seller by company, domain and address, never by a similar name.
MEDVi names three pharmacies, all 503A. Hims sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like: Hims and MEDVi publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed. MEDVi states you can cancel at any time; refunds: full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed.
Neither Hims nor MEDVi pays us. Links to them earn nothing. Scores: Hims 6.7, MEDVi 7.7.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks